Introduction
The cure rate of childhood acute lymphoblastic leukemia (ALL) has been greatly improved by the development of disease-specific and risk-specific chemotherapies combined with sufficient sanctuary therapy [1] . In addition, progress in the management of nutriOffprint requests to: H. Tanaka Received: August 29, 2002 / Accepted: November 11, 2002 patient's mother or father. Table 1 shows a summary of patient profiles. All patients had received prophylactic CI (18) (19) (20) (21) (22) (23) (24) . The 16 patients who received only chemotherapy and CI were assigned to group A, which consisted of patients who were in pubertal growth at evaluation, or group B, which consisted of patients who had attained final height at evaluation. The remaining 5 patients (group C) were patients who had been given stem cell transplantation (SCT) or testis irradiation (TI), and these patients were analyzed separately. Three males received SCT; 1 a peripheral blood stem cell transplantation (PBSCT), 1 an auto-bone marrow transplantation (BMT), and 1 an allo-BMT with total body irradiation (TBI; 12 Gy) from a matched sibling donor. Two males had testicular involvement and received TI (24 Gy) in addition to CI. All the patients in groups A and B had received combined chemotherapy with prednisolone, vincristine, l-asparaginase, methotrexate, and 6-mercaptopurine, and 5 patients had also received anthracycline. No patients in this study had had central nervous system involvement, or any history of hormone replacement therapy including human growth hormone, thyroid hormones, or sex steroids.
Linear growth
Standing height was measured at the time of diagnosis, at cessation of therapy, and at evaluation. The data obtained was converted to Z scores based on sex-and age-matched Japanese standards. Final height was defined as a change in height Ͻ 1 cm during a 1-year period of observation, and catch-up growth was defined as an increase in height Z score between cessation of therapy and evaluation in this study.
Endocrinological analysis
For all patients, serum calcium, alkaline phosphatase (ALP), thyroid function [free thyroxine (FT3, FT4); thyroid-stimulating hormone (TSH)], luteinizing hormone (LH), follicle-stimulating hormone (FSH), and insulin-like growth factor 1 (IGF-1) were assessed at the time of evaluation. IGF-1 values were converted to Z scores based on sex-and age-matched Japanese standards. Testosterone levels were measured in males. Estradiol levels could not be measured in this study because of the low sensitive assays (detection limit, 10 pg/ml) for this age group. Bone age at evaluation was analyzed using the TW2 radius-ulna-short bones method. The onset of the puberty was determined by testicular enlargement (larger testicular size than 4 ml by orchidmeter) for males and mammary development at Tanner II stage for females [9] .
BMD and metabolic bone markers
BMD at the lumbar spine and metabolic bone markers were assessed at evaluation. BMD at the second to fourth lumbar spine (L2-L4) was measured by dualenergy X-ray absorptiometry (QDR-1000W; Hologic, Waltham, MA, USA). BMD at the lumbar spine was converted into Z scores calculated according to standard values for Japanese [10] .
We measured serum bone-specific alkaline phosphatase (B-ALP) and carboxy-terminal propeptide of type 1 collagen (P1CP) as markers for bone formation, and serum carboxy-terminal cross-linked telopeptide of type 1 collagen (1CTP) and urinary collagen type 1 N-telopeptides/creatinine (U-NTx/Cr) as markers for bone resorption. These markers were determined by Otsuka Tokyo Assay Laboratories (Tokyo, Japan). UNTx/Cr was measured in spot urine samples, which were collected as the second void of the day. B-ALP, P1CP, and 1CTP were converted to Z scores using sex-and age-matched data from our published Japanese controls [11, 12] .
Statistics
Changes in height Z scores during the observation periods (at diagnosis, at cessation of therapy, and at evaluation) were compared using a paired t test. Correlations were examined between each of the factors related to therapy and to parameters of growth or bone metabolism. Differences between pubertal survivors with or without catch-up growth and after cessation of therapy were tested using Mann-Whitney U tests (P Ͻ 0.05 was considered significant). Statistical analyses were performed using Statview version 5.0 (Abacus Concepts, Berkeley, CA, USA).
Results

Linear growth
All patients in group A who had received their leukemia therapy before the appearance of pubertal signs showed age-matched pubertal development at evaluation. To investigate the effect of therapy on pubertal growth, changes in height Z scores were analyzed in group A. Individual height Z scores are shown in Fig. 1 . Height Z scores decreased during treatment in all patients. The annual changes in height Z scores during therapy [(height Z score at cessation of therapy Ϫ height Z score at diagnosis)/therapy duration (year)] was follows: median Ϫ0.19 SD, range Ϫ0.42 to Ϫ0.07. In contrast, after the cessation of therapy, changes in height Z scores showed high patient-to-patient variability (annual changes in height Z scores after cessation of therapy [(height Z score at evaluation Ϫ height Z score at cessation of therapy)/observation periods after cessation of therapy (year)]: median 0.04 SD, range Ϫ0.11 to 0.19). All patients height Z scores at evaluation decreased compared to their scores at diagnosis [differences in height Z scores during observation periods (height Z score at evaluation Ϫ height Z score at diagnosis): median Ϫ0.64 SD, range Ϫ1.06 to Ϫ0.09]. The data for linear growth are summarized in Table 2 . The annual changes in height Z scores during therapy correlated significantly with the annual changes between cessation of therapy and evaluation (r ϭ Ϫ0.76, P ϭ 0.004). No significant relationship was found between these changes in height Z scores and gender, chronological age (at diagnosis, at cessation of therapy, and at evaluation), height Z scores (at diagnosis, at cessation of therapy, and at evaluation), duration of therapy, or Z scores of IGF-1, B-ALP, P1CP, or 1CTP. However, the U-NTx/Cr level was significantly higher in patients without catch-up growth compared to those with catchup growth (P ϭ 0.01) (Fig. 2) . Of the patients given only chemotherapy and CI (group B), five attained their final height (163-170 cm in males, 145-158 cm in females) during the observation period. Their target heights (TH), which are calculated by the following equation for prediction of final height in Japan, were 169-176 cm in males and 154-160 cm in females: TH ϭ [(PH ϩ 13) ϩ MH]/2 ϩ 2 cm (males) and [(PH Ϫ 13) ϩ MH]/2 ϩ 2 cm (females), where PH is paternal height and MH is maternal height [13] . It ranged within Ϯ 1.0 SD of the standard adult height for Japanese. Thus, we did not assess their final height by the final height/TH ratio in this study. In this group, all the patients had reached pubertal age by cessation of therapy. All their height Z scores decreased during therapy and three of their scores decreased after cessation of therapy. As a result, all the patients in Group B had decreased height Z scores at final height compared to those at diagnosis (differences in height Z scores after diagnosis to final height: median Ϫ0.99 SD, range Ϫ1.92 to Ϫ0.56).
The patients who received SCT or TI tended to have more severe growth impairment (differences in height Z scores after diagnosis to evaluation: median Ϫ1.83 SD, range Ϫ2.10 to Ϫ0.47). All cases in this group had decreased height Z scores not only during therapy but also after cessation of therapy (annual changes in height Z scores after cessation of therapy: median Ϫ0.12 SD, range Ϫ0.29 to Ϫ0.01).
Endocrinological analysis
Serum calcium, ALP, and thyroid hormones showed normal values in all patients (see Table 2 ). The difference between chronological age and bone age was within 2 years in all patients.
Among the patients who received chemotherapy and CI (groups A and B), no patient showed a low IGF-1 Z score of less than Ϫ2 SD. No patient showed abnormal values for gonadotropin or abnormal pubertal development in these groups. All females who were older than 11 years at evaluation have undergone spontaneous menarche.
In group C, one male who had received auto-BMT showed a slightly elevated TSH (5.25 µU/ml), with normal FT4 and FT3 levels. All group C patients, except for one, showed an IGF-1 Z score of less than Ϫ2 SD. The two males who received TI showed especially low IGF Z scores, at about Ϫ3.7 SD. Only one male who received auto-PBSCT showed an appropriate IGF Z score for age, at 0.9 SD. The two males who received TI were found to have hypergonadotropic hypogonadism on endocrinological examination, but showed pubertal growth and development. They started sex hormone replacement therapy after this diagnosis.
Bone density and metabolic bone markers
The L2-L4 BMD Z scores at evaluation tended to be low. Of the 16 patients in groups A and B, 13 patients showed L2-L4 BMD Z scores less than the mean. Of those 13, 3 showed BMD Z scores lower than Ϫ1 SD, and 1 patient showed BMD Z scores lower than Ϫ2 SD. In group C, 1 patient who had received TI showed a low BMD Z score of about Ϫ4.3 SD, and 2 patients showed BMD Z scores lower than Ϫ1 SD (Table 3) .
In examining bone formation markers, we found that B-ALP Z scores tended to be high in the patients of groups A and B, but that these scores did not correlate with age, changes in height Z scores, or L2-L4 BMD. None of the patients in any group showed a Z score of less than Ϫ2 SD of B-ALP and P1CP. As for bone resorption markers, ICTP Z scores were within a normal range for all patients. In group A, the U-NTx/Cr values were significantly higher in the patients without catch-up growth (see Fig. 2 ). All the U-NTx/Cr values in the patients without catch-up growth were above the normal limit. In group B, the U-NTx/Cr values were within healthy adult levels. In group C, all three patients who received TI or TBI showed high U-NTx/Cr levels, above 100 nmol bone collagen equivalent (BCE)/mmol Cr.
Discussion
Attainment of normal growth is important to the quality of life in survivors of childhood malignancy. ALL is the most common malignancy in childhood, and several authors have already studied growth in ALL survivors. However, there has been little consensus on the longitudinal growth of individual survivors. In this study, the individual growth periods of ALL survivors were classified into treatment and posttreatment periods. A prominent decline in the growth rate was observed in the treatment period, whereas the growth rate after treatment varied significantly among individuals.
Schriock et al. reported that the incidence of growth attenuation during treatment was approximately 90% [14] . In the current study, all our patients uniformly showed reduced height Z scores during treatment. Although younger age and taller height Z scores were previously reported as risk factors [15] , we found no correlation between reductions in height Z scores during treatment and any clinical factor such as gender, age, time of diagnosis, or height Z score at diagnosis in this study.
After the completion of therapy, the growth rate can be expected to increase [2, 14] . However, these reports showed that this growth recovery may be transient, and that subsequent growth rate could decrease in some patients. In the current study, height Z scores were also found to change in varying degrees from one individual to another. Therefore, we next analyzed endocrinological factors affecting catch-up growth in puberty.
In pubertal survivors who had received leukemia therapy during the prepubertal period, there was a negative correlation between changes in height Z scores after cessation of therapy and those during therapy; that is, growth recovery after cessation of therapy was better in patients whose growth was more severely affected by therapy. This homeostatic phenomenon suggests that pubertal growth may be able to compensate for preceding growth attenuation. In addition, there was a discrepancy of height Z scores at evaluation between group A and B, that is, lower height Z scores at final height in group B. Although these two groups were not comparable directly, this discrepancy suggested that growth attenuation during puberty could affect final height more seriously.
Nevertheless, this growth recovery during puberty might be restrictive, because all our patients showed a decrease in height Z score at evaluation compared to their scores at diagnosis. This limitation might be partially due to CI, because it has been reported that patients treated without CI may experience catch-up growth sufficient to compensate for the preceding period of decrease [16] .
However, Sklar et al. reported that patients without CI might have a reduced height standard deviation score even after treatment [17] . Holm et al. explained this discrepancy by the intensity of the employed chemotherapy regimen [16] . Thus, many therapeutic and age-dependent factors contribute to catch-up growth. Previously, in addition to CI [16, 18] , both CIinduced abnormal hypothalamopituitary hormone secretion [15, 19, 20] and therapy-induced early puberty [17, 21, 22] were mainly considered to be the causes of blunted catch-up growth. In the current study, persistent abnormal GH secretion was not proven to be a major cause of subsequent attenuated growth in patients receiving chemotherapy and CI. However, low IGF-1 Z scores were found in patients who received SCT or TI.
Pubertal survivors without catch-up growth showed high U-NTx/Cr values for their age. A previous report analyzed 1CTP as a bone resorption marker, and concluded that normal bone turnover could be expected in survivors who attained their final height [23] . In this study, B-ALP, P1CP, and 1CTP Z scores were within normal range in all patients, regardless of whether they had attained their final height, while all our pubertal survivors without catch-up growth had U-NTx/Cr values above the normal limits. U-NTx/Cr values are relatively higher in childhood, although the normal range in adolescence is about 200-400 nmol BCE/mmol Cr [24] . Considering bone resorption status, there was a discrepancy between U-NTx/Cr values and 1CTP Z scores in Values are expressed as median (range) ALP, alkaline phosphatase; P1CP, carboxy-terminal propeptide of type 1 collagen; 1CTP, carboxy-terminal cross-linked telopeptide of type 1 collagen; NTx, N-telopeptide; Cr, creatinine; BCE, bone collagen equivalent our results; that is, pubertal survivors without catch-up growth showed normal 1CTP Z scores in spite of UNTx/Cr above the normal limits. This discrepancy could be explained by the difference between NTx and 1CTP. Some reports have documented that ICTP may not always reflect bone resorption status correctly [25] .
Thus, endocrinological disorders that induced a high bone resorption status should be considered as causes of blunted catch-up growth in puberty. From our endocrinological analysis, males in group A without catch-up growth tended to have higher LH levels with higher testosterone levels compared to those with catch-up growth, but the difference was not statistically significant (Table 4 ). The FSH levels were similar between these two groups, although we could not measure the estradiol level because of assay limitation and estrogen is important for bone maturation, even in males [26] . CI may affect hypothalamopituitary functions and cause abnormal early puberty or hypogonadotropic hypogonadism. In these patients, no apparent abnormal puberty was noted in group A; however, the difference in the tendency to subtle hypergonadism with premature completion of bone growth or hypogonadism with continuation of linear growth may result in a difference in the occurrence of catch-up growth. It was reported that gonadal dysfunction followed normal pubertal development in patients receiving BMT [27] . Subtle gonadal damage despite of normal pubertal development is also probable in childhood ALL survivors.
In summary, we demonstrated that catch-up growth after drug cessation varied from patient to patient. We also suggested that subtle gonadal dysfunction during puberty might cause blunted catch-up growth. Gonadal function should be discussed more carefully, not only from the aspect of fertility but also from that of growth attenuation. Their pubertal development especially should be followed, and endocrinological intervention may be considered even from the early phase of the deranged pubertal development. Because of considerable differences in catch-up growth among individuals, each patient should be carefully followed up from various aspects, including precise endocrinological evaluation. 
